Revenue: As of FY2025 Q3, the actual value is USD 18.94 K, missing the estimate of USD 20 K.EPS: As of FY2025 Q3, the actual value is USD -2.93.EBIT: As of FY2025 Q3, the actual value is USD -1.956 M.<h3>Segment Revenue</h3><ul><li>Total revenues for the three months ended September 30, 2025, were $18,942, an increase of $4,535 or 31.5% compared to $14,407 for the same period in 2024. For the nine months ended September 30, 2025, total revenues were $57,251, an increase of $21,759 or 61.3% from $35,492 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit (Loss): For the three months ended September 30, 2025, gross profit was $4,386 compared to a loss of - $6,925 in 2024. For the nine months ended September 30, 2025, gross profit was $5,037 compared to a loss of - $28,610 in 2024.</li><li>Operating Expenses: Total operating expenses for the three months ended September 30, 2025, were $1,835,350, an increase of $546,317 from $1,289,033 in 2024. For the nine months ended September 30, 2025, operating expenses were $5,064,434, an increase of $1,386,217 from $3,678,217 in 2024.</li><li>Net Loss: For the three months ended September 30, 2025, net loss was - $1,706,294 compared to - $1,366,176 in 2024. For the nine months ended September 30, 2025, net loss was - $5,344,487 compared to - $5,003,355 in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was - $5,536,766, an increase from - $4,348,747 in 2024.</li><li>Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $16,601,882, compared to $4,900,996 in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company expects revenue growth to continue as more insurance payors are brought on board and scan volumes increase. The company believes its current cash will fund operating expenses and capital expenditure requirements through the first quarter of 2027.</li><li>Non-Core Business: The company raised an additional $2.5 million in October 2025 through a registered direct public offering to fund market development, clinical evidence, product development, and general corporate purposes.</li></ul>

Aclarion | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 18.94 K